- Portfolio Prep for Next Week: 'Don't Get Crazy'
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Surprising Options Trades in TiVo Shares
- 10 Dividend Picks For Your Portfolio: Chief Investors
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Retail Earnings and Sales to Improve in Q4: Analyst
- 4 Food Stocks to Stuff in Your Portfolio: Analyst
- S&P at 1050-1200 Trading Range Next Year: Strategist
MOST SHARED
- Tiger Woods Out of Hospital After Accident
- The Good Entrepreneur Winner
- Global Selloff From Dubai Woes Shows Signs of Winding Down
- Get Paid Six Figures to Wear a T-Shirt?
- Halftime Report: Dubai - First Ripple Of Larger Crisis?
- Next Week: Cash In Now Or Wait For A Santa Rally?
- Longer Lines, Fuller Carts This Black Friday
- US Will Have to Tax Consumers: Economist
- U.S. Stocks Fall on Dubai Worries
- Black Friday at Best Buy
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Longer Lines, Fuller Carts This Black Friday
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Obama's Emission Reduction Pledge Paints Future for Autos
- Is Super Bowl Halftime Act Too Old?
- Surprising Options Trades in TiVo Shares
- EA Sports Hopes to Pump Up Sales Through Pop-Up Locations
- Next Week: Cash In Now Or Wait For A Santa Rally?
- Fed Audit Would Hurt Economic Prospects: Bernanke
- Dubai Stock Selloff May Bring Buying Opportunity
- Longer Lines, Fuller Carts This Black Friday
- Big US Banks May Be Forced to Raise Capital: Bove
- Bank of America Amends Pay for Senior Executives
- Tiger Woods Out of Hospital After Accident
- Dubai Fallout Is a Correction, Not Another Crisis: El-Erian
- Dubai's Debt Woes Signal New Era for Creditors
RSS FEED
CNBC Stock Blog
Text Size 
Pharmaceutical companies may not have been immune to the weak economy, but its effects on pharma “have not been as dramatic as some of the other sectors,” said Catherine Arnold, senior pharmaceuticals analyst at Credit Suisse.
Pfizer reported a better-than-expected profit as cost-cutting helped offset sharply lower sales of its cholesterol fighter and its anti-smoking drug on Tuesday morning, while Bristol-Myers Squibb said its profit slipped 3 percent, as negative foreign exchange factors and falling sales of its cancer medicine more than offset higher revenue from other medicines.
“Although neither [Pfizer or Bristol-Myers Squibb] are necessarily the major pharmaceuticals that produce anti-viral medicine for pandemics, big drug companies do play a role in having an important mission,” said Arnold.
She named her favorite makers of anti-viral drugs.
Arnold's Picks:
Roche
Gilead [GILD
Loading...
()
]
GlaxoSmithKline [GSK
Loading...
()
]
Arnold also said she has an outperform rating on Pfizer [PFE
Loading...
()
] and a neutral rating on Bristol-Myers Squibb [BMY
Loading...
()
].
More Swine Flu News From CNBC.com
- Companies Start Initial Work on Vaccine
- Deathtoll Rises in Mexico
- Flu Impact: Latin America Stock IndexesDisclosure:
Arnold does not own shares of any of the companies mentioned above.
Data is a real-time snapshot *Data is delayed at least 15 minutes